Figure 2From: Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials MADRS Remission Rate. (A) Patients with baseline MADRS total scores ≥20; (B) patients with baseline CGI-BP-D severity scores ≥4; (C) patients with a mixed episode at baseline. CGI-BP-D = Clinical Global Impression for Bipolar Disorder-Depression scale; MADRS = Montgomery-Asberg Depression Rating Scale. *P < 0.05; † P ≤ 0.01; ‡ P ≤ 0.001 vs placebo. **P < 0.05; †† P ≤ 0.01 vs olanzapine.Back to article page